AstraZeneca India Received Regulatory Approval for Durvalumab

AstraZeneca Pharma India has received regulatory approval for Durvalumab for liver cancer treatment in India, marking a significant step in expanding cancer care options.

The approval allows the company to introduce this immunotherapy drug for patients with unresectable hepatocellular carcinoma, a common form of liver cancer where surgery is not possible.

The Durvalumab for liver cancer treatment in India approval specifically applies to adult patients who have not received prior systemic therapy. This makes the drug a first-line treatment option, giving doctors an additional tool in cases where early intervention can make a meaningful difference.

Also Read: India's Rare Disease Shift Driven by PRIP and PLI Policies

Durvalumab, globally known as Imfinzi, is an immunotherapy drug that works by helping the immune system detect and fight cancer cells more effectively. It has already been approved for multiple cancers worldwide, including lung and bladder cancer, and its expansion into liver cancer treatment highlights growing confidence in immunotherapy-based approaches.

For India, where liver cancer is often diagnosed at advanced stages, this approval addresses a critical gap. Many patients are not eligible for surgery, making systemic therapies the only viable path. With this development, AstraZeneca India liver cancer treatment portfolio becomes stronger, offering new hope for patients with limited options.

The move also reflects AstraZeneca’s continued focus on oncology in India, particularly in bringing advanced cancer therapies to the market. As demand rises for innovative treatments, approvals like this could reshape how liver cancer is managed in the country.